ライフサイエンスコーパス: biomarker

1 0.87, which is comparable to established CSF biomarkers).

2 at tag diversity may be used as a predictive biomarker.

3 Voltammetry (DPV) as it is a very important biomarker.

4 overy by providing XIAP as a pharmacodynamic biomarker.

5 r 14 of the drugs, 9 of which had no genomic biomarker.

6 t central disease-associated DNA methylation biomarkers.

7 redicted C-IRIS and are potential predictive biomarkers.

8 from >200 candidate variables, including 109 biomarkers.

9 nd for all WHO grades (AUC, 0.899) among all biomarkers.

10 of cell-to-cell communication mechanisms and biomarkers.

11 rall survival, and to correlate relapse with biomarkers.

12 r characterise associations with imaging and biomarkers.

13 can be developed for detection of other DNA biomarkers.

14 oxicity and no photobleaching of fluorescent biomarkers.

15 cleolar size and activity can serve as aging biomarkers.

16 lished clinical risk factors, and diagnostic biomarkers.

17 non-motor assessments, DAT imaging, and CSF biomarkers.

18 record is hampered by a lack of unambiguous biomarkers.

19 ions and shortcomings of previously proposed biomarkers.

20 without additional adjustment for individual biomarkers.

21 y recapitulates an Alzheimer-like profile of biomarker abnormalities even in the absence of other hal

22 re than 90% of men and women had one or more biomarker abnormalities.

23 shown to specifically bind the angiogenesis biomarker alpha V beta 3 integrin.

24 Proteolytic neuronal injury biomarkers (alphaII-spectrin breakdown products, SBDPs)

25 Reported as a cancer biomarker, AMF secretion into body fluids might be close

26 roach to estimate public health status using biomarker analysis in wastewater.

27 es a clinically-relevant neuroimaging ageing biomarker and demonstrates that combining distinct measu

28 c platform provides a unique opportunity for biomarker and pathway discovery after myocardial injury.

29 ing techniques hold considerable promise for biomarker and pathway discovery, in spite of the lack of

30 et clinical demands for the discovery of new biomarkers and development of treatment solutions to ben

31 openia index using routinely available renal biomarkers and evaluate its association with muscle mass

32 ogy datasets to investigate prognostic image biomarkers and genotype-phenotype associations.

33 Next, we discuss the use of biomarkers and how clinicians may be able to use them in

34 s evaluated associations between HDL-related biomarkers and incident CVD.

35 n addition, analyses of multiple biochemical biomarkers and metabolomic profiles suggested that MPs e

36 ial of RNA splice variants to serve as novel biomarkers and molecular targets for developmental thera

37 Metabolites can be useful as early biomarkers and new targets to promote early intervention

38 g or after treatment, measurement of cardiac biomarkers and other surrogate endpoints, and in some ca

39 We delineate the different types of biomarkers and provide a general assessment of the curre

40 It is important to find biomarkers and targets to improve metastatic PCa diagnos

41 arthritis, and provides potential diagnostic biomarkers and therapeutic targets.

42 mes, have immediate potential for serving as biomarkers and therapeutics in dermatology over the next

43 ains unknown, hampering the search for novel biomarkers and treatments.

44 nd inform development of clinically relevant biomarkers and trials of combination therapies.

45 al PET readings may influence the use of CSF biomarkers and/or amyloid PET assessment in clinical pra

46 We review post-mortem, serum-biomarker, CSF-biomarker, and neuroimaging studies that have examined b

47 l specifications, sensing mechanisms, target biomarkers, and analytical performance of the paper bios

48 n DED are tear film osmolarity, inflammatory biomarkers, and meibomian gland imaging.

49 for disease mechanisms, identify new disease biomarkers, and reposition drugs for diseases with unmet

50 laques; coronary artery calcification; serum biomarkers; and lifestyle.

51 Current AD biomarkers are expensive and/or invasive and therefore u

52 Structural retinal imaging biomarkers are important for early recognition and monit

53 Reliable response biomarkers are needed to identify responders, and conven

54 eveloped and independently cross-validated a biomarker assay to predict mortality based on genes whos

55 s a rapid, inexpensive, high sensitivity CVD biomarker assay.

56 samples scored for H&E sTILs and 427 for CD8 biomarker assessments.

57 oangiogenic factor MMP9 may play a role as a biomarker associated with the development of PML in MS p

58 ion-weighted MR imaging could reveal imaging biomarkers associated with cognition in active professio

59 A biomarker-based cancer diagnosis may significantly impro

60 Purpose Biomarker-based clinical trials provide efficiencies dur

61 In fact, should any of the biomarkers be nonexistent, the signal remains turned-off

62 etection is not only serving as an apoptosis biomarker, but also is of great importance to understand

63 n signatures are commonly used as predictive biomarkers, but do not capture structural features withi

64 D with inflammatory and endothelial function biomarkers, but most work has been cross-sectional and d

65 Data from new diagnostic biomarkers can be combined with the clinical features of

66 er type to determine whether combinations of biomarkers can be used as predictors of VTE.

67 ferential gene expression analysis to select biomarker candidates by considering their topological di

68 studies, while the role of MS in translating biomarker candidates to clinical diagnostics is less pro

69 tics could help discover clinically relevant biomarker combinations pivotal for understanding cardiov

70 d investigated determinants of the vitamin D-biomarker concentrations in both populations.We used dat

71 om a food-frequency questionnaire and plasma biomarker concentrations that were collected simultaneou

72 gh to accommodate varying levels of pretrial biomarker confidence within the same platform structure

73 ng and the discovery of reliable blood-based biomarkers could be useful for the disease progress moni

74 d have higher mortality rates and that these biomarkers could improve risk stratification of poor out

75 We review post-mortem, serum-biomarker, CSF-biomarker, and neuroimaging studies that

76 As such, biomarkers currently used to delineate eosinophilic infl

77 nts of carbohydrates, amino acids, bacterial biomarkers (D-amino acids), and plant protein biomarkers

78 chromatography-mass spectrometry (LC-MS) for biomarker determination using ProGastrin Releasing Pepti

79 studies are necessary for robust nutritional biomarker development and validation.

80 o therapy and to offer new avenues for blood biomarker development.

81 e of the lipidome increase the likelihood of biomarker discovery and could lead to more comprehensive

82 metry (MS) have been successfully applied in biomarker discovery studies, while the role of MS in tra

83 e to clinical proteomics and particularly to biomarker discovery studies.

84 de range of applications, including clinical biomarker discovery, drug discovery, environmental chemi

85 ploit these phenomena for cancer therapy and biomarker discovery.

86 t are being evaluated in subtype-specific or biomarker-driven clinical trials.

87 Mephedrone was selected as a suitable biomarker due to its high stability profile in wastewate

88 The measurement of urinary biomarkers during ex vivo normothermic kidney perfusion

89 correlations between ascorbic acid and other biomarkers (e.g., amyloid-beta40, total and phosphorylat

90 re, it is important to be able to detect CVD biomarkers early so that patients can be diagnosed prope

91 sent the new platform to sensitively measure biomarkers electrochemically to pg/ml range with insigni

92 Phase II studies with biomarker evaluation are ongoing.

93 ompletely defined and no reliable predictive biomarkers exist.

94 orm the interpretation of iron and vitamin A biomarkers (ferritin, serum transferrin receptor, and re

95 merged: workup of patients with symptoms and biomarker findings suggestive of NET, but with negative

96 Cmya5 is an expression biomarker for a number of diseases affecting striated mu

97 d that HL-FeNPs could be used as fluorescent biomarker for Al(3+) in live whole organisms.

98 checkpoint and suggesting it as a candidate biomarker for ATR inhibitor therapy.

99 O, which was further confirmed as a specific biomarker for BAT imaging using [(18)F]-F-DPA, a TSPO-sp

100 Exosomes constitute an emerging biomarker for cancer diagnosis because they carry multip

101 evated TGs level in blood over 500mg/dL is a biomarker for cardiovascular diseases, Alzheimer disease

102 plore the use of allergen-specific IgG4 as a biomarker for compliance.

103 There is no biomarker for diagnosing active tuberculosis in patients

104 s or sporadic forms - and holds promise as a biomarker for diagnosis and novel drug discovery.

105 irculating exosome holds great potentials as biomarker for diagnosis and prognosis of human cancers.

106 Shape is an important biomarker for E. gracilis, serving as an indicator of bi

107 R-125a-3p is readily accessible as diagnosis biomarker for early-stage colon cancer.

108 serve as a quantitatively useful predictive biomarker for efficacious responses to cancer immunother

109 Conclusion MPO is a suitable imaging biomarker for identifying and tracking inflammatory dama

110 findings encourage future trials of MMN as a biomarker for individual assignment, prediction, and/or

111 olesterol esterification fraction is a valid biomarker for liver synthesis and allows reliable predic

112 oroazomycinarabinoside ((18)F-FAZA) is a PET biomarker for noninvasive identification of regional tum

113 n easily acquired, noninvasive, and low-cost biomarker for self-control ability.

114 leasing Peptide (ProGRP), a highly sensitive biomarker for Small Cell Lung Cancer, as a model.

115 Urinary calprotectin is a promising biomarker for the differentiation of prerenal and intrin

116 , which then serve to identify the universal biomarker for the influenza virus, M1 protein.

117 llary light reflex may represent a surrogate biomarker for the integrity of the retinohypothalamic tr

118 s from our framework can be used as a robust biomarker for the prediction of prognosis and treatment

119 d the presence of these cells may serve as a biomarker for the use of Notch pathway inhibitors in com

120 s in colorectal cancer and a potential novel biomarker for this disease.

121 , which will acquire some novel and clinical biomarkers for appropriate diagnosis and treatment to ca

122 n cancer processes and potentially useful as biomarkers for cancer diagnosis and prognosis.

123 uated the potential of microRNAs (miRNAs) as biomarkers for cardiometabolic disease.

124 ing approaches and introducing novel imaging biomarkers for diagnosis and treatment evaluation of inf

125 ism of pathogenesis and identifying clinical biomarkers for disease classification.

126 ssues, rendering these CpGs novel epigenetic biomarkers for heart failure.

127 scle-specific miRNAs may be useful molecular biomarkers for monitoring the progress of muscle wasting

128 ond BRCA1/2 mutations, there are no approved biomarkers for olaparib in high-grade serous ovarian can

129 l exposure to genotoxicants and can serve as biomarkers for risk assessment.

130 n human patients, could represent predictive biomarkers for risk evaluation.

131 ion, blood-derived miRNAs might be promising biomarkers for SZ diagnosis.

132 To assess the value of exosome miRNAs as biomarkers for T1DM, miRNA expression in plasma-derived

133 Thus, the discovery of reliable biomarkers for the management of TBI would improve clini

134 Prognostic biomarkers for the pancreatic neuroendocrine tumors are

135 -carboxamide, that can be used as validation biomarkers for the treatment.

136 Here we characterized potential predictive biomarkers for treatment with AsiDNA, a novel first-in-c

137 We measured biomarkers from plasma samples collected in 211 patients

138 in delivering drugs or extracting diagnostic biomarkers from skin.

139 patternMarkers ascertainment of data-driven biomarkers from whole-genome data.

140 kdown products, SBDPs) and glial cell injury biomarker, glial fibrillary acidic protein (GFAP)-breakd

141 iomarkers (D-amino acids), and plant protein biomarkers (hydroxyproline).

142 PLC-derived organoids are amenable for biomarker identification and drug-screening testing and

143 There are no biomarkers identifying patients at-risk, or guiding mech

144 nd constitutes a tentative surrogate imaging biomarker in diabetes.

145 ancers, and it may be utilized as a valuable biomarker in early diagnostics and prognostication of th

146 oplasmic)-negative) is a reliable prognostic biomarker in ER positive breast cancer patients, and pre

147 d for individual patients and as a surrogate biomarker in intervention trials.

148 s been investigated as a putative anatomical biomarker in MR-based studies of Mn toxicity.

149 ore, the validation of an exosome-associated biomarker in the blood of patients provides novel, and l

150 appears to be a promising minimally invasive biomarker in the preoperative diagnosis of ACC but needs

151 Future studies should measure multiple biomarkers in each cancer type to determine whether comb

152 -type specific signatures with corresponding biomarkers in GTEx data, illustrating GWCoGAPS and patte

153 environment, making these molecules pivotal biomarkers in many disease processes.

154 trol participants in the U-BIOPRED (Unbiased Biomarkers in Prediction of Respiratory Disease Outcomes

155 NSE), a traumatic brain injury (TBI) protein biomarker, in diluted blood plasma samples, achieving a

156 stics of carcinogens; incorporate epigenetic biomarkers, in silico modelling, high-performance comput

157 h drug sensitivity patterns identifies novel biomarkers, including a signature outperforming RAS/RAF

158 The treatment-by-biomarker interaction was statistically significant for

159 pre-approval trials and 2) the treatment-by-biomarker interaction.

160 Due to the delay in the implementation of biomarkers into clinical practice and the association wi

161 l variables, comorbidities, medications, and biomarkers into Cox proportional hazards models for each

162 ting for predictive and prognostic molecular biomarkers involve selection of assays, type of specimen

163 e-wide association analyses for twenty serum biomarkers involved in organ function and reproductive h

164 athy is poorly understood, and no prognostic biomarker is currently available.

165 Whether this is true for other biomarkers is unknown.

166 larities but, crucially, some differences in biomarker levels (IL-1beta and sRANKL) and bacterial spe

167 We also evaluated associations between biomarker levels and sociodemographic, physical, dietary

168 Thanks to the high throughput acquisition of biomarker levels in G. fossarum exposed in four referenc

169 Biomarker levels were log-transformed.

170 No differences in CSF biomarker levels were observed between treatment groups.

171 V infection would attenuate changes in these biomarker levels.

172 and intracellular accumulation of the aging biomarker lipofuscin.

173 In addition, the discovery of novel biomarkers may not only prove useful in predicting sever

174 ntraclass correlation coefficients (ICCs) of biomarkers measured in 24-h urine samples that were coll

175 ined associations of trauma/PTSD status with biomarkers measured twice, 10 to 16 years apart, in card

176 , electrocardiography, echocardiography, and biomarker measurement (NT-proBNP, high-sensitive troponi

177 Associations between repeated biomarker measurements and the primary endpoint were ass

178 electrochemical detection of a breast cancer biomarker microRNA (miRNA), mir-21 was achieved via elec

179 us percutaneous coronary intervention) and 4 biomarkers (midkine, adiponectin, apolipoprotein C-I, an

180 deposition in HC, suggesting that these two biomarkers might be used to detect at risk individuals.

181 We identified a two-biomarker model in the derivation cohort that predicted

182 lso nonlesional skin and blood, more complex biomarker models of AD are needed.

183 althy adult samples may help to identify the biomarkers needed to detect nonsymptomatic, preclinical

184 The ambiguity of conceiving TSPO simply as a biomarker of 'neuroinflammation' or 'microglial activati

185 ic damages, TSPO has generally turned into a biomarker of 'neuroinflammation' or 'microglial activati

186 DNA methylation (DNAm) can be used as a biomarker of cell types, and through deconvolution appro

187 ure is easily imaged, and may be a surrogate biomarker of cerebral and systemic vascular risk in pati

188 he suggestion that semen quality is a strong biomarker of general health.

189 processing capacity that could be used as a biomarker of injury for outcome prediction or target for

190 GR target, the transcription factor c-Myc (a biomarker of non-healing wounds), in porcine and human w

191 OPN-HpAb (0.801, P = 0.006), as well as one-biomarker of PGI/II (0.735, P < 0.001), HpAb (0.737, P <

192 ts, we recommend testosterone as a sensitive biomarker of POP exposure and that seasonal patterns are

193 ity in the normal esophagus using an imaging biomarker of radiation-response and esophageal toxicity,

194 nd increased Bcl-xL expression: the latter a biomarker of senescence and target of anti-senescence th

195 Our data also point to a potential biomarker of target engagement for early clinical studie

196 oxycholesterol (24[S]-HC), which serves as a biomarker of target engagement, and CSF protein biomarke

197 The best biomarker of vitamin D status, 25hydroxyvitamin D3 (25(O

198 d tissues, they can also be used as cellular biomarkers of a variety of different disease states and

199 disease mechanisms and to identify reliable biomarkers of amyotrophic lateral sclerosis (ALS), a pro

200 iomarkers of protective immunity however the biomarkers of attenuation in the parasite preparations h

201 etic resonance imaging methods that quantify biomarkers of brain tissue microstructure, integrating d

202 aging have the potential to serve as imaging biomarkers of breast cancer recurrence risk.

203 In this study a set of unique biomarkers of commonly found oregano adulterants became

204 se patient trials, but the lack of validated biomarkers of disease progression presents a challenge w

205 endogenous elastin degradation, are possible biomarkers of disease severity and progression in bronch

206 sponses to anti-cancer treatment can uncover biomarkers of drug sensitivity.

207 As could serve as promising and sought-after biomarkers of endometrial receptivity, fertility and inf

208 enatal iAs exposure in participants from the Biomarkers of Exposure to ARsenic (BEAR) pregnancy cohor

209 Biomarkers of exposure to PFRs were measured for the fir

210 INTERPRETATION: Biomarkers of fibrillar tau deposition can be included w

211 ed to validate the effect of these potential biomarkers of fibrosis.

212 lomics for the search of potential surrogate biomarkers of GHB consumption.

213 bles the identification and selection of new biomarkers of human exposure to drugs with scarce or unk

214 xolitinib for one week significantly reduced biomarkers of inflammation and fibrosis.

215 The availability of predictive imaging biomarkers of inflammation and neurological damage in HI

216 consistency in the association between these biomarkers of inflammation and renal outcomes in DKD.

217 Biomarkers of macronutrient intake are lacking.

218 Moreover, the identification of potential biomarkers of outcome measures, availability of relevant

219 ate urinary NP and BPA levels in relation to biomarkers of oxidative/nitrative stress and inflammatio

220 rations; however, relevant animal models and biomarkers of progression in patients with RP are needed

221 Such studies typically examined the biomarkers of protective immunity however the biomarkers

222 l analytical framework for identification of biomarkers of public exposure to chemicals via combined

223 There is a significant need to find biomarkers of response to radiotherapy and cetuximab in

224 To identify novel biomarkers of senescence, we immunized BALB/c mice with

225 omics and transcriptomics) to identify novel biomarkers of thiazide diuretics BP response.

226 l processes and also recognized as potential biomarkers of various health disorders.

227 duals with MCI had data on neurodegeneration biomarkers; of these patients, 107 were Abeta-N+ (22.8%;

228 l participants had data on neurodegeneration biomarkers; of these, 52 were Abeta-N+ (24.9%; 30 FDG+,

229 We evaluated the expression of brain injury biomarkers on postsurgical brain tissue obtained from 20

230 lopments in biosensing approaches for cancer biomarker owes much credit to functionalized nanomateria

231 ons and restricts the full interpretation of biomarker performance.

232 9%), all clinical studies were restricted to biomarker-positive patients (enriched).

233 sting, we describe 1) the use of enrichment (biomarker-positive patients) and a randomized controlled

234 Biomarkers predicting these outcomes are needed.

235 aining of toxic amyloid plaques, a potential biomarker present in the Alzheimer's disease (AD) brain

236 Antigen 19-9 (CA 19-9), a pancreatic cancer biomarker, produce optically tunable substrates with two

237 A combination of seven plasma metabolite biomarkers readily discriminates supraphysiological gluc

238 Plasma biomarkers reflecting activation of procoagulation and a

239 The Biomarkers Reflecting Inflammation and Nutritional Deter

240 8413) and WRA (4 surveys; n = 4258) from the Biomarkers Reflecting the Inflammation and Nutritional D

241 concurrent development of neurophysiological biomarkers relevant to SZ pathology in order to inform D

242 on using the ethyl glucuronide (EtG) alcohol biomarker resulted in increased alcohol abstinence in ou

243 The biomarker results revealed multiphasic dose-response cur

244 ited significantly higher viability and CD45 biomarker retention compared to untreated controls.

245 After a recovery period, all biomarkers returned to levels approaching those observed

246 inland, Australia, Sweden, and France), with biomarkers sampled between 1970 and 2010.

247 of this study was to develop a clinical and biomarker score to predict the presence of significant C

248 show the higher biological relevance of the biomarkers selected by our approach.

249 sensitive and selective SPR chip for folate biomarker sensing in serum.

250 with the aim of identifying potential renal biomarkers; several characteristic mid-IR spectral marke

251 mor incorporating both clinical features and biomarkers should be considered.

252 Herein we explored whether urinary proteomic biomarkers specific for different forms of arthritis (rh

253 ute-phase proteins and certain micronutrient biomarkers such as C-reactive protein (CRP), alpha-1-aci

254 Our hypothesis states that tumor-specific biomarkers such as entropy should be correlated between

255 pathology, especially when incorporated with biomarkers such as miRNAs, quantitative imaging features

256 istration (FDA) and required pharmacogenomic biomarker testing, we describe 1) the use of enrichment

257 hat GlcSph is a more selective and sensitive biomarker than GlcCer for neuronopathic GD in preclinica

258 ther, these data highlight several potential biomarkers that can be used in a blood-based panel to al

259 Multi-modal MRI techniques have identified biomarkers that could help to predict whether someone wi

260 We investigated the usefulness of new biomarkers that have either enhanced liver specificity (

261 and neck squamous cell carcinoma (HNSCC) and biomarkers that predict altered immunity, thereby enabli

262 urthermore, there are currently no validated biomarkers that predict which mRCC patients will benefit

263 n ongoing challenge is the identification of biomarkers that predict which patients will benefit from

264 but also for possibly identifying peripheral biomarkers that will eliminate the need for scalp biopsi

265 ntiating the RBC deformability (a mechanical biomarker) that is highly correlated with the infection

266 ry evidence from experimental and behavioral biomarkers, that blockade of the V1a receptor may improv

267 lves, as well as in combination with the top biomarkers (the combination being our a priori primary e

268 These biomarkers therefore may play an important role in the m

269 atment, we also identified potential disease biomarkers through transcriptomic profiling.

270 ltiple tumor microenvironment components and biomarkers throughout a tumor.

271 eased IL17A levels in BALF may be a valuable biomarker to identify severe MPP in children.

272 so puts forward a potential novel prognostic biomarker to predict high-risk tumors before they metast

273 tion of the complex in tumours and candidate biomarkers to analyse its effect on cells and tissues.

274 that MR parameters may be used as sensitive biomarkers to detect fibrotic tissue deposition and fibe

275 liver function and the incorporation of new biomarkers to help manage CHB require further exploratio

276 establish clinical, serological, and imaging biomarkers to identify high-risk patients, and clinical

277 Development of standardized assays for novel biomarkers toward better defining hepatitis B virus cure

278 MG is explored as a significant biomarker towards the prediction of diabetic complicatio

279 in insights into the genetic architecture of biomarker traits which can reflect health status.

280 a, in whom there was no evidence of abnormal biomarkers typically associated with Crohn's disease.

281 flux through these pathways should generate biomarkers useful for in vivo dose responses of beta-lap

282 n vivo OCT imaging of LVYE-1 showed that the biomarker was significantly down-regulated during inflam

283 The clinical significance of these potential biomarkers was further tested.

284 lly, epidemiological validation of candidate biomarkers was performed in two community-based studies.

285 that reliable qualitative identification of biomarkers was possible for analytes >15 ng/mL.

286 sterin and interleukin-18, all other urinary biomarkers were elevated at earlier time points compared

287 marker of target engagement, and CSF protein biomarkers were evaluated.

288 and unexpectedly, in 82% of models, the top biomarkers were expression based.

289 The biomarkers were identified to level 1 according to the m

290 Several new biomarkers were identified with altered expression in an

291 In this study, 16 drug biomarkers were selected, including the parent forms and

292 e of recognising its diagnostic criteria and biomarker, which would be of great relevance to either o

293 the correlation of 10 previously identified biomarkers with clinical outcomes after allogeneic HCT.

294 challenging, due in part to a lack of robust biomarkers with predictive value, some optimism has come

295 multiple studies have correlated individual biomarkers with transformation.

296 ndidates for ROC analysis and found multiple biomarkers with values areas under the curve >0.70 inclu

297 bgroups based on the endophenotype [panel of biomarkers]) with the aim to refine the management of th

298 d for the quantitative monitoring of genetic biomarkers within communities through the analysis of wa

299 e pathways that involved in these prognostic biomarkers would be beneficial for the regression to NGR

300 pid approaches for quantitative detection of biomarkers would drastically impact global health by ena